Aytu BioPharma subleases 22,909 sq ft of manufacturing facility to AMTMS; to expand to entire facility by Dec 2024

AYTU BIOPHARMA, INC

Subleases 22,909 sq ft (~30%) of Grand Prairie, TX facility to AMTMS; base rent $20,045/mo through Dec 2023, then $21,000/mo until expansion.
Expansion to entire 77,112 sq ft facility by Dec 31, 2024; rent rises to $70,686/mo. Security deposit of $90,731.
CEO says sublease reduces monthly operating expenses, supports margin improvement for ADHD products; longer-term plan to transfer manufacturing to contract manufacturer.
AMTMS is a new CMO; will use facility for nutraceutical and pharmaceutical manufacturing.

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AYTU BIOPHARMA, INC entered into Sublease Agreement with AMT Manufacturing Solutions, LLC (effective 2023-04-27).

Action: entry
Agreement: lease
Counterparty: AMT Manufacturing Solutions, LLC
Effective: 2023-04-27

Exact text from the filing

On April 27, 2023, Aytu BioPharma, Inc., through its wholly-owned subsidiary, Neos Therapeutics, LP, (“Aytu” or the “Company”) and AMT Manufacturing Solutions, LLC (“AMTMS”) entered into an agreement for Aytu to sublease 22,909 square feet of its manufacturing facility in Grand Prairie, Texas (“Sublease Agreement”).

View on SEC.gov

Browse all material agreements →

AYTU BIOPHARMA, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-007404

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.